BiotechTube
Diazyme Laboratories

Diazyme Laboratories

San Diego, United States· Est.
diazyme.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

Diazyme Laboratories, founded in 1998 and headquartered in San Diego, is a privately-held diagnostics company with a mature commercial-stage business. It has built a robust portfolio of clinical chemistry and immunoassay reagents, with a significant new strategic focus on developing blood-based biomarker tests for neurodegenerative diseases like Alzheimer's. The company operates a vertically integrated model from R&D to global distribution, leveraging its core expertise in enzymology and immunoturbidimetric/chemiluminescence assay formats to serve the clinical laboratory market.

NeurologyGastroenterologyInflammationRenalMetabolic

Technology Platform

Proprietary enzyme-based assays, latex-enhanced immunoturbidimetric assays, and chemiluminescence immunoassay (CLIA) technologies for use on open-system automated clinical analyzers.

Funding History

2
Total raised:$12M
Debt$10M
Grant$2M

Opportunities

The global shift towards blood-based biomarkers for Alzheimer's disease represents a multi-billion dollar market opportunity, driven by new disease-modifying therapies requiring accurate diagnosis and monitoring.
Diazyme's established distribution network to clinical labs provides a significant commercial advantage for launching its neurology pipeline.
The growing demand for cost-effective, automated routine and specialty diagnostics in aging populations supports its core business.

Risk Factors

The neurology pipeline faces significant regulatory hurdles and must achieve clinical adoption in a competitive landscape with well-funded rivals.
Rapid evolution in the science of blood-based biomarkers poses a risk that current targets may become obsolete.
As a private company, scaling manufacturing and commercial efforts for the new pipeline may strain financial resources.

Competitive Landscape

In routine diagnostics, Diazyme competes with large IVD conglomerates (Roche, Abbott, Siemens) and other open-system reagent suppliers. In the emerging neurology blood test space, competition includes highly sensitive immunoassay platform companies (Quanterix), large diagnostics firms developing their own assays (Roche, Fujirebio), and a growing number of specialized biotech startups, making differentiation on performance, price, and lab workflow critical.

More companies in Diagnostics & Precision Medicine →More companies in United States →